{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:01:50Z","timestamp":1792710110977,"version":"4.5.0"},"reference-count":81,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Richter syndrome (RS) is the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Two pathologic variants of RS are recognized: namely, the diffuse large B-cell lymphoma (DLBCL) variant and the rare Hodgkin lymphoma (HL) variant. Histologic documentation is mandatory to diagnose RS. The clinical suspicion of RS should be based on clinical signs and symptoms. Differential diagnosis between CLL progression and RS and choice of the biopsy site may take advantage of positron emission tomography\/computed tomography. Molecular lesions of regulators of proliferation (CDKN2A, NOTCH1, MYC) and apoptosis (TP53) overall associate with \u223c90% of DLBCL-type RS, whereas the biology of the HL-type RS is largely unknown. The prognosis of the DLBCL-type RS is unfavorable; the outcome of HL-type RS appears to be better. The most important RS prognostic factor is the clonal relationship between the CLL and the aggressive lymphoma clones, with clonally unrelated RS having a better prognosis. Rituximab-containing combination chemotherapy for DLBCL is the most widely used treatment in DLBCL-type RS. Fit patients who respond to induction therapy should be offered stem cell transplantation (SCT) to prolong survival. Adriamycin, bleomycin, vinblastine, and dacarbazine is the preferred regimen for the HL-type RS, and SCT consolidation is less used in this condition.<\/jats:p>","DOI":"10.1182\/blood-2018-01-791376","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T15:15:14Z","timestamp":1524582914000},"page":"2761-2772","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":181,"title":["Biology and treatment of Richter syndrome"],"prefix":"10.1182","volume":"131","author":[{"given":"Davide","family":"Rossi","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"},{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Spina","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111906141376900_B1","first-page":"180","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume-title":"World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"M\u00fcller-Hermelink","year":"2008"},{"issue":"10","key":"2019111906141376900_B2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"2019111906141376900_B3","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111906141376900_B4","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111906141376900_B5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2019111906141376900_B6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"issue":"11","key":"2019111906141376900_B7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"suppl 1","key":"2019111906141376900_B8","first-page":"4286","article-title":"PD-1 expression in chronic lymphocytic leukemia and large B-cell Richter transformation (DLBCL-RT): a distinguishing feature for DLBCL-RT and promising surrogate marker for clonal relatedness [abstract]","volume":"130","author":"He","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2019111906141376900_B9","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"2019111906141376900_B10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum Pathol"},{"issue":"15","key":"2019111906141376900_B11","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111906141376900_B12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111906141376900_B13","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"2019111906141376900_B14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"issue":"7354","key":"2019111906141376900_B15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"14","key":"2019111906141376900_B16","doi-asserted-by":"crossref","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","article-title":"Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia","volume":"114","author":"Fabbri","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2019111906141376900_B17","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","article-title":"Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8","volume":"125","author":"Gounari","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111906141376900_B18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2019111906141376900_B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"2019111906141376900_B20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111906141376900_B21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111906141376900_B22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111906141376900_B23","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111906141376900_B24","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2019111906141376900_B25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"9583","key":"2019111906141376900_B26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"2019111906141376900_B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10428194.2012.710327","article-title":"The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)","volume":"54","author":"Solh","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111906141376900_B28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111906141376900_B29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111906141376900_B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111906141376900_B31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"2019111906141376900_B32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2014.104661","article-title":"Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion","volume":"99","author":"Strati","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2019111906141376900_B33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"2019111906141376900_B34","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2019111906141376900_B35","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111906141376900_B36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111906141376900_B37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111906141376900_B38","article-title":"Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\u2013results from pre-planned interim analysis of the randomized phase 3 Murano study [abstract]","volume":"130","author":"Seymour","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111906141376900_B39","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter\u2019s syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111906141376900_B40","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"issue":"18","key":"2019111906141376900_B41","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111906141376900_B42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2019111906141376900_B43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2019111906141376900_B44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V130.Suppl_1.834.834","article-title":"Analysis of PET-CT to identify Richter\u2019s transformation in 167 patients with disease progression following kinase inhibitor therapy [abstract]","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111906141376900_B45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2222","article-title":"XIV. The pathology of transformation of indolent B cell lymphomas","volume":"33","author":"Gascoyne","year":"2015","journal-title":"Hematol Oncol"},{"issue":"15","key":"2019111906141376900_B46","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019111906141376900_B47","first-page":"2995","article-title":"Clinical outcome and prognostic factors of patients with Richter\u2019s syndrome: retrospective multicenter study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC) [abstract]","volume":"130","author":"Abrisqueta","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111906141376900_B48","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111906141376900_B49","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"suppl 15","key":"2019111906141376900_B50","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1200\/jco.2011.29.15_suppl.6508","article-title":"Activity and tolerability of the Bruton\u2019s tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): interim results of a phase Ib\/II study [abstract]","volume":"29","author":"Byrd","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019111906141376900_B51","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy [abstract]","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111906141376900_B52","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111906141376900_B53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111906141376900_B54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111906141376900_B55","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2019111906141376900_B56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter\u2019s syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111906141376900_B57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111906141376900_B58","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"18","key":"2019111906141376900_B59","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111906141376900_B60","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111906141376900_B61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V128.22.60.60","article-title":"Acalabrutinib monotherapy in patients with Richter transformation from the phase 1\/2 ACE-CL-001 clinical study [abstract]","volume":"128","author":"Hillmen","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111906141376900_B62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111906141376900_B63","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2019111906141376900_B64","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111906141376900_B65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial [abstract]","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"suppl 13","key":"2019111906141376900_B66","article-title":"The clinical study on CD19-directed chimeric antigen receptor-modified T cells in patient with Richter Syndrome [abstract]","volume":"77","author":"Xia","year":"2017","journal-title":"Cancer Res"},{"issue":"21","key":"2019111906141376900_B67","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1182\/blood.V124.21.5660.5660","article-title":"Evolution to plasmablastic lymphoma (PBL) after CAR-T cell therapy in a case of SLL\/CLL with Richter\u2019s transformation [abstract]","volume":"124","author":"Evans","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111906141376900_B68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111906141376900_B69","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: the MD Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111906141376900_B70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111906141376900_B71","first-page":"785","article-title":"Hodgkin\u2019s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res"},{"issue":"3","key":"2019111906141376900_B72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111906141376900_B73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejca.2003.09.031","article-title":"Second malignancies and Richter\u2019s syndrome in patients with chronic lymphocytic leukaemia treated with cladribine","volume":"40","author":"Robak","year":"2004","journal-title":"Eur J Cancer"},{"issue":"2","key":"2019111906141376900_B74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V94.2.448","article-title":"Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases","volume":"94","author":"Mauro","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111906141376900_B75","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111906141376900_B76","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111906141376900_B77","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V112.11.3179.3179","article-title":"Richter transformation of chronic lymphocytic leukemia: incidence, risk factors and outcome [abstract]","volume":"112","author":"Alipour","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111906141376900_B78","first-page":"306b","article-title":"Richter\u2019s syndrome in B-CLL: report of 37 cases [abstract]","volume":"10","author":"Tabuteau","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2019111906141376900_B79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2019111906141376900_B80","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111906141376900_B81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2004.09.008","article-title":"Richter\u2019s transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis","volume":"29","author":"Thornton","year":"2005","journal-title":"Leuk Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/25\/2761\/1466063\/blood791376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/25\/2761\/1466063\/blood791376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T18:12:41Z","timestamp":1661019161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/25\/2761\/37138\/Biology-and-treatment-of-Richter-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":81,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,6,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-01-791376","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]}}}